All Pharma News
Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine

Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine
GLOBENEWSWIRE
20 Jun 2024
Share Share
Vaxxinity retreats from `abusive relationship` of public market

Vaxxinity retreats from `abusive relationship` of public market
Annalee Armstrong FIERCE BIOTECH
15 May 2024
Share Share
Vaxxinity To Voluntarily Delist, Deregister Class A Common Stock

Vaxxinity To Voluntarily Delist, Deregister Class A Common Stock
GLOBENEWSWIRE
19 Apr 2024
Share Share
Vaxxinity Issues Shareholder Letter

Vaxxinity Issues Shareholder Letter
GLOBENEWSWIRE
19 Apr 2024
Share Share
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology Meeting

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology Meeting
GLOBENEWSWIRE
28 Mar 2024
Share Share
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results
GLOBENEWSWIRE
27 Mar 2024
Share Share
Vaxxinity Announces Positive Data from Phase 1 Trial for Parkinson™s Disease

Vaxxinity Announces Positive Data from Phase 1 Trial for Parkinson™s Disease
GLOBENEWSWIRE
07 Mar 2024
Share Share
Vaxxinity™s Cholesterol Vaccine Candidate Successfully Lowers LDL-C

Vaxxinity™s Cholesterol Vaccine Candidate Successfully Lowers LDL-C
GLOBENEWSWIRE
15 Feb 2024
Share Share
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
GLOBENEWSWIRE
13 Feb 2024
Share Share
Vaxxinity Announces Research Collaboration on Active Immunotherapies

Vaxxinity Announces Research Collaboration on Active Immunotherapies
GLOBENEWSWIRE
30 Jan 2024
Share Share